Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Genzyme General, Pharming, Synpac Inc. deal

WIR Staff
April 24, 2000 7:00 AM UTC

Synpac granted GENZ exclusive worldwide rights to develop and commercialize Synpac's Pompase recombinant human alpha-glucosidase as an enzyme replacement therapy for Pompe's disease. In addition, GENZ and its partner PHAR plan to share funding of Pompase development. Synpac will receive $19.5 million from GENZ, and PHAR will issue a convertible note to GENZ for $10 million. ...